# Chemed Corp: Form 10-Q for the period ended Mar 31, 2025

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2025-04-28
- Accepted by EDGAR: Apr 28, 2025, 09:06 ET
- Period: 2025-03-31
- Accession: 0001562762-25-000096
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000156276225000096/che-20250331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000156276225000096/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $646.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $430.5m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $105.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-01-01 to 2025-03-31 | $94.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-01-01 to 2025-03-31 | $329.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | $23.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-01-01 to 2025-03-31 | $71.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-01-01 to 2025-03-31 | $4.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-01-01 to 2025-03-31 | $4.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 14,764,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2025-01-01 to 2025-03-31 | $32.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2025-01-01 to 2025-03-31 | $13.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2025-01-01 to 2025-03-31 | $7.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2025-01-01 to 2025-03-31 | $33.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-03-31 | $173.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $502.4m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $1.73bn | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $290.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $544.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-03-31 | $1.18bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2025-03-31 | 14,629,484 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 28,826 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world. We continue to monitor macroeconomic trends and uncertainties such as inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, which may have adverse effects on net sales and profitability. Based on preliminary analysis of the potential effects of the announced tariffs and these other factors, we do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2025. However, we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2026 planning. Economic pressures including the challenges of high inflation and the effects of increased tariffs may negatively affect our net sales and profitability in the future.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Service revenues and sales | **$646,943** | $589,233 |
| Net income | **$71,757** | $65,017 |
| Diluted EPS | **$4.86** | $4.24 |
| Adjusted net income | **$83,074** | $79,831 |
| Adjusted diluted EPS | **$5.63** | $5.20 |
| Adjusted EBITDA | **$121,692** | $114,622 |
| Adjusted EBITDA as a % of revenue | **18.8%** | 19.5% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 30-31.

For the three months ended March 31, 2025, the increase in consolidated service revenues and sales was driven by a 15.1% increase at VITAS and by a 1.8% increase at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of a 11.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 3.2%. Acuity mix shift negatively impacted revenue growth by 112-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 112-basis points. The increase in service revenues at Roto-Rooter was driven by an increase in excavation and water restoration offset by a decrease in plumbing and drain cleaning.

On April 17, 2024, VITAS completed the purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc d/b/a/ Covenant Care (“Covenant”) for an aggregated purchase price of $85.0 million in cash.

Revenue for the Covenant acquisition for the first three months of 2025 was approximately $11.5 million to $12.5 million and this translated to net income of approximately $1.8 million to $2.0 million. Adjusted EBITDA in the quarter attributed to Covenant is between $2.5 million and $2.7 million.

The pro forma revenue and earnings for the Company for the three months ended March 31, as if the Covenant acquisition made in 2024 was completed on January 1, 2024 are as follows (in thousands, except per share data):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Service revenues and sales | **$646,943** | $604,081 |
| Net income | **$71,757** | $68,679 |
| Earnings per share | **$4.91** | $4.54 |
| Diluted earnings per share | **$4.86** | $4.48 |

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2024 to March 31, 2025 include the following:

A $114.7 million increase in accounts receivable due to the reclassification of the OAS deposit of $47.0 million. Other significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $57.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

A $47.3 million decrease in other assets primarily related to the reclassification of the OAS deposit from a long-term receivable to accounts receivable.

A $3.8 million increase in lease right of use asset due to lease renewals. This resulted in a similar increase in the lease liability accounts.

A $3.5 million increase in accounts payable due to timing of payments.

A $30.7 million decrease in income taxes payable due to timing of payments.

A $32.2 million decline in accrued compensation due primarily to the payment of 2024 bonuses in the first quarter of 2025.

Net cash provided by operating activities decreased $51.8 million from March 31, 2024 to March 31, 2025. The main drivers are a increase of $72.8 million due to accounts receivable offset by a $20.4 million decline in accounts payable.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

### Commitments and Contingencies

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2025, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and/or term loan by an additional $250.0 million.

We have issued $45.5 million in standby letters of credit as of March 31, 2025, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of March 31, 2025, we have approximately $404.5 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2025 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

### Results of Operations

### Three months ended March 31, 2025 versus 2024 - Consolidated Results

Our service revenues and sales for the first quarter of 2025 increased 9.8% versus services and sales revenues for the first quarter of 2024. Of this increase, a $53.4 million increase was attributable to VITAS, and a $4.3 million increase at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

| VITAS | Three months ended March 31, 2025 | 2024 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **$351,566** | $304,860 | 15.3 |
| General inpatient | **34,022** | 30,303 | 12.3 |
| Continuous care | **24,637** | 24,169 | 1.9 |
| Other | **5,344** | 4,084 | 30.9 |
| Subtotal | **415,569** | 363,416 | 14.4 |
| Medicare cap adjustment | **(2,325)** | (2,375) | 2.1 |
| Room and board - net | **(3,525)** | (2,944) | (19.7) |
| Implicit price concessions | **(2,319)** | (4,090) | 43.3 |
| Net revenue | **$407,400** | $354,007 | 15.1 |
| Roto-Rooter |  |  |  |
| Drain cleaning | **$59,542** | $61,621 | (3.4) |
| Plumbing | **46,059** | 48,098 | (4.2) |
| Excavation | **64,239** | 58,618 | 9.6 |
| Other | **186** | 244 | (23.8) |
| Subtotal - short term core | **170,026** | 168,581 | 0.9 |
| Water restoration | **54,163** | 46,678 | 16.0 |
| Independent contractors | **18,362** | 19,616 | (6.4) |
| Outside franchisee fees | **1,424** | 1,491 | (4.5) |
| Other | **4,895** | 6,015 | (18.6) |
| Gross revenue | **248,870** | 242,381 | 2.7 |
| Implicit price concessions | **(9,327)** | (7,155) | (30.4) |
| Net revenue | **239,543** | 235,226 | 1.8 |
| Total Revenues | $646,943 | $589,233 | 9.8 |

Days of care at VITAS during the quarters were as follows:

|  | Three months ended March 31, 2025 | 2024 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **1,632,569** | 1,447,912 | 12.8 |
| Nursing home | **307,108** | 283,158 | 8.5 |
| Respite | **9,995** | 7,752 | 28.9 |
| Subtotal routine homecare and respite | **1,949,672** | 1,738,822 | 12.1 |
| General inpatient | **29,704** | 26,645 | 11.5 |
| Continuous care | **22,620** | 24,037 | (5.9) |
| Total days of care | **2,001,996** | 1,789,504 | 11.9 |

The increase in service revenues at VITAS is comprised primarily of a 11.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 3.2%. Acuity mix shift negatively impacted revenue growth by 112-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 112-basis.

The decrease in drain cleaning revenues for the first quarter of 2025 versus 2024 is attributable to a 3.2% increase in price and service mix offset by a 6.6% decrease in job count. The decrease in plumbing revenues for the first quarter of 2025 versus 2024 is attributable to a 3.3% decrease in price and service mix shift and a 0.9% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, excavation revenues increased 9.6% and water restoration revenues increased 16.0%. Contractors operations decreased 6.4%.

The consolidated gross margin was 33.5% in the first quarter of 2025 as compared with 34.6% in the first quarter of 2024. On a segment basis, VITAS’ gross margin was 23.2% in the first quarter of 2025 essentially equal to first quarter of 2024. The Roto-Rooter segment’s gross margin was 50.9% for the first quarter of 2025 as compared with 51.9% in the first quarter of 2024.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | **$103,760** | $98,418 |
| Long-term incentive compensation | **2,657** | 9,121 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | **(830)** | 8,334 |
| Total SG&A expenses | **$105,587** | $115,873 |

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2025 were up 5.4% when compared to first quarter of 2024 due mainly to normal salary increases and an increase in variable selling expenses.

Other income – net comprise (in thousands):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Interest income | **$2,076** | $4,243 |
| Market value adjustment on assets held in deferred compensation trusts | **(830)** | 8,334 |
| Other | **(1)** | - |
| Total other income - net | **$1,245** | $12,577 |

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. Chemed invests excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Income tax provision calculated at the statutory federal rate | **$20,092** | $17,742 |
| State and local income taxes | **4,187** | 2,961 |
| Stock compensation tax benefits | **(463)** | (3,297) |
| Other--net | **101** | 2,062 |
| Income tax provision | **$23,917** | $19,468 |
| Effective tax rate | 25.0% | 23.0% |

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| Roto-Rooter | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Amortization of reacquired franchise agreements | **$(1,806)** | $(1,804) |
| Corporate |  |  |
| Stock option expense | **(7,621)** | (7,555) |
| Long-term incentive compensation | **(2,353)** | (3,415) |
| Severance arrangement | **-** | (5,337) |
| Excess tax benefits on stock compensation | **463** | 3,297 |
| Total | **$(11,317)** | $(14,814) |

### Three months ended March 31, 2025 versus 2024 - Segment Results

Net income/(loss) for the first quarter of 2025 versus the first quarter of 2024 by segment (in thousands):

|  | Three months ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| VITAS | **$50,030** | $43,970 |
| Roto-Rooter | **39,944** | 40,853 |
| Corporate | **(18,217)** | (19,806) |
|  | **$71,757** | $65,017 |

After-tax earnings as a percent of revenue at VITAS in the first quarter of 2025 was 12.3% as compared to 12.4% in the first quarter of 2024.

Roto-Rooter’s after-tax earnings as a percent of revenue in the first quarter of 2025 was 16.7%, as compared to 17.4% in the first quarter of 2024.

After-tax Corporate expenses for the first quarter of 2025 decreased 8.0% when compared to the first quarter in 2024 due primarily to a $6.3 million decrease in stock-based compensation offset by a $2.2 million decrease in interest income and a $2.8 million decrease in excess tax benefits on stock compensation.

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2025*

*(in thousands)(unaudited)*

| 2025 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Service revenues and sales** | **$407,400** | **$239,543** | **$-** | **$646,943** |
| **Cost of services provided and goods sold** | **312,807** | **117,723** | **-** | **430,530** |
| **Selling, general and administrative expenses** | **26,538** | **62,649** | **16,400** | **105,587** |
| **Depreciation** | **5,196** | **8,237** | **12** | **13,445** |
| **Amortization** | **26** | **2,546** | **-** | **2,572** |
| **Other operating expense/(income)** | **64** | **(13)** | **-** | **51** |
| **Total costs and expenses** | **344,631** | **191,142** | **16,412** | **552,185** |
| **Income/(loss) from operations** | **62,769** | **48,401** | **(16,412)** | **94,758** |
| **Interest expense** | **(48)** | **(132)** | **(149)** | **(329)** |
| **Intercompany interest income/(expense)** | **5,296** | **3,930** | **(9,226)** | **-** |
| **Other income—net** | **48** | **10** | **1,187** | **1,245** |
| **Income/(expense) before income taxes** | **68,065** | **52,209** | **(24,600)** | **95,674** |
| **Income taxes** | **(18,035)** | **(12,265)** | **6,383** | **(23,917)** |
| **Net income/(loss)** | **$50,030** | **$39,944** | **$(18,217)** | **$71,757** |
| **(a) The following amounts are included in net income (in thousands):** |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Pretax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(9,091)** | **$(9,091)** |
| **Long-term incentive compensation** | **-** | **-** | **(2,657)** | **(2,657)** |
| **Amortization of reacquired franchise agreements** | **-** | **(2,352)** | **-** | **(2,352)** |
| **Total** | **$-** | **$(2,352)** | **$(11,748)** | **$(14,100)** |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **After-tax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(7,621)** | **$(7,621)** |
| **Long-term incentive compensation** | **-** | **-** | **(2,353)** | **(2,353)** |
| **Amortization of reacquired franchise agreements** | **-** | **(1,806)** | **-** | **(1,806)** |
| **Excess tax benefits on stock compensation** | **-** | **-** | **463** | **463** |
| **Total** | **$-** | **$(1,806)** | **$(9,511)** | **$(11,317)** |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2024*

*(in thousands)(unaudited)*

| 2024 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $354,007 | $235,226 | $- | $589,233 |
| Cost of services provided and goods sold | 271,896 | 113,231 | - | 385,127 |
| Selling, general and administrative expenses | 23,792 | 61,260 | 30,821 | 115,873 |
| Depreciation | 5,166 | 8,108 | 13 | 13,287 |
| Amortization | 26 | 2,495 | - | 2,521 |
| Other operating expense | 7 | 85 | - | 92 |
| Total costs and expenses | 300,887 | 185,179 | 30,834 | 516,900 |
| Income/(loss) from operations | 53,120 | 50,047 | (30,834) | 72,333 |
| Interest expense | (46) | (117) | (262) | (425) |
| Intercompany interest income/(expense) | 5,194 | 3,442 | (8,636) | - |
| Other income—net | 29 | 22 | 12,526 | 12,577 |
| Income/(expense) before income taxes | 58,297 | 53,394 | (27,206) | 84,485 |
| Income taxes | (14,327) | (12,541) | 7,400 | (19,468) |
| Net income/(loss) | $43,970 | $40,853 | $(19,806) | $65,017 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(9,026) | $(9,026) |
| Severance arrangement | - | - | (5,337) | (5,337) |
| Long-term incentive compensation | - | - | (3,784) | (3,784) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Total | $- | $(2,352) | $(18,147) | $(20,499) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(7,555) | $(7,555) |
| Severance arrangement | - | - | (5,337) | (5,337) |
| Long-term incentive compensation | - | - | (3,415) | (3,415) |
| Amortization of reacquired franchise agreements | - | (1,804) | - | (1,804) |
| Excess tax benefits on stock compensation | - | - | 3,297 | 3,297 |
| Total | $- | $(1,804) | $(13,010) | $(14,814) |

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2025 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $50,030 | **$39,944** | **$(18,217)** | **$71,757** |
| **Add/(deduct):** |  |  |  |  |
| **Interest expense** | **48** | **132** | **149** | **329** |
| **Income taxes** | **18,035** | **12,265** | **(6,383)** | **23,917** |
| **Depreciation** | **5,196** | **8,237** | **12** | **13,445** |
| **Amortization** | **26** | **2,546** | **-** | **2,572** |
| **EBITDA** | **73,335** | **63,124** | **(24,439)** | **112,020** |
| **Add/(deduct):** |  |  |  |  |
| **Intercompany interest expense/(income)** | **(5,296)** | **(3,930)** | **9,226** | **-** |
| **Interest income** | **(49)** | **(10)** | **(2,017)** | **(2,076)** |
| **Stock option expense** | **-** | **-** | **9,091** | **9,091** |
| **Long-term incentive compensation** | **-** | **-** | **2,657** | **2,657** |
| **Adjusted EBITDA** | **$67,990** | **$59,184** | **$(5,482)** | **$121,692** |
|  |  |  |  | Chemed |
| For the three months ended March 31, 2024 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $43,970 | $40,853 | $(19,806) | $65,017 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 46 | 117 | 262 | 425 |
| Income taxes | 14,327 | 12,541 | (7,400) | 19,468 |
| Depreciation | 5,166 | 8,108 | 13 | 13,287 |
| Amortization | 26 | 2,495 | - | 2,521 |
| EBITDA | 63,535 | 64,114 | (26,931) | 100,718 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (5,194) | (3,442) | 8,636 | - |
| Interest income | (29) | (22) | (4,192) | (4,243) |
| Stock option expense | - | - | 9,026 | 9,026 |
| Severance arrangement | - | - | 5,337 | 5,337 |
| Long-term incentive compensation | - | - | 3,784 | 3,784 |
| Adjusted EBITDA | $58,312 | $60,650 | $(4,340) | $114,622 |

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Net income as reported | **$71,757** | $65,017 |
| Add/(deduct) pre-tax cost of: |  |  |
| Stock option expense | **9,091** | 9,026 |
| Long-term incentive compensation | **2,657** | 3,784 |
| Amortization of reacquired franchise agreements | **2,352** | 2,352 |
| Severance arrangement | **-** | 5,337 |
| Add/(deduct) tax impacts: |  |  |
| Tax impact of the above pre-tax adjustments (1) | **(2,320)** | (2,388) |
| Excess tax benefits on stock compensation | **(463)** | (3,297) |
| Adjusted net income | **$83,074** | $79,831 |
| Diluted Earnings Per Share As Reported |  |  |
| Net income | **$4.86** | $4.24 |
| Average number of shares outstanding | **14,764** | 15,339 |
| Adjusted Diluted Earnings Per Share |  |  |
| Adjusted net income | **$5.63** | $5.20 |
| Adjusted average number of shares outstanding | **14,764** | 15,339 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |  |  |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| Homecare | **$351,566** | $304,860 |
| Inpatient | **34,022** | 30,303 |
| Continuous care | **24,637** | 24,169 |
| Other | **5,344** | 4,084 |
| Subtotal | **$415,569** | $363,416 |
| Room and board, net | **(3,525)** | (2,944) |
| Contractual allowances | **(2,319)** | (4,090) |
| Medicare cap allowance | **(2,325)** | (2,375) |
| Total | **$407,400** | $354,007 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |
| Homecare | **84.6%** | 83.9% |
| Inpatient | **8.2** | 8.3 |
| Continuous care | **5.9** | 6.7 |
| Other | **1.3** | 1.1 |
| Subtotal | **100.0** | 100.0 |
| Room and board, net | **(0.8)** | (0.8) |
| Contractual allowances | **(0.6)** | (1.1) |
| Medicare cap allowance | **(0.6)** | (0.7) |
| Total | **98.0%** | 97.4% |
| Days of care |  |  |
| Homecare | **1,632,569** | 1,447,912 |
| Nursing home | **307,108** | 283,158 |
| Respite | **9,995** | 7,752 |
| Subtotal routine homecare and respite | **1,949,672** | 1,738,822 |
| Inpatient | **29,704** | 26,645 |
| Continuous care | **22,620** | 24,037 |
| Total | **2,001,996** | 1,789,504 |
| Number of days in relevant time period | **90** | 91 |
| Average daily census (days) |  |  |
| Homecare | **18,140** | 15,911 |
| Nursing home | **3,412** | 3,112 |
| Respite | **111** | 85 |
| Subtotal routine homecare and respite | **21,663** | 19,108 |
| Inpatient | **330** | 293 |
| Continuous care | **251** | 264 |
| Total | **22,244** | 19,665 |
| Total Admissions | **18,139** | 16,911 |
| Total Discharges | **17,875** | 16,170 |
| Average length of stay (days) | **118.7** | 103.9 |
| Median length of stay (days) | **16.0** | 16.0 |
| ADC by major diagnosis |  |  |
| Cerebro | **44.7%** | 43.6% |
| Neurological | **12.4** | 13.4 |
| Cancer | **9.6** | 10.1 |
| Cardio | **16.1** | 16.1 |
| Respiratory | **7.2** | 7.2 |
| Other | **10.0** | 9.6 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Cerebro | **28.4%** | 27.7% |
| Neurological | **6.5** | 7.5 |
| Cancer | **24.6** | 24.6 |
| Cardio | **15.0** | 15.6 |
| Respiratory | **11.6** | 10.8 |
| Other | **13.9** | 13.8 |
| Total | **100.0%** | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | **0.6%** | 1.1% |
| Accounts receivable -- |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **47.3** | 42.3 |
| Days of revenue outstanding- including unapplied Medicare payments | **44.5** | 34.3 |

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

## Market risk

As filed, 572 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2025, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 845 characters.

We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,735 characters.

**Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.**

Both Roto-Rooter’s and VITAS’s primary businesses are the provision of services within the United States. Accordingly, they are likely to be less affected by the impact of specific or wide-ranging tariffs than many other entities in the United States and Global economies. However, significant tariffs on certain products, such as steel for Roto-Rooter’s cabling machines and pharmaceuticals utilized by VITAS, could materially increase the costs of Roto-Rooter and VITAS. Additionally, because our service businesses heavily rely on delivering service to customers or patients in their residences, increases in the costs of vehicle acquisition, maintenance, repair, and reimbursement for employees’ use of personal vehicles, could have a significant increase on our expenses.

These additional costs, in the case of VITAS, cannot be passed along to our patients because of the structure of hospice reimbursement, and in the case of Roto-Rooter, may not be able to be fully passed along to our customers. These additional costs could materially adversely affect our margins.

To the extent that tariffs cause any adverse impacts on global supply chains, it could further materially affect the ability of both businesses to timely source critical supplies, which may affect our delivery of services.

If, as a result of tariffs, the United States’ economy experiences a recession or other economic slowdown, the demand for Roto-Rooter’s non-emergency services may decline materially.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Filed Apr 28, 2025.
Source: SEC EDGAR, the filing index for accession 0001562762-25-000096. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
